BillTracking.org
Back to the feed

Home › US bills › H.R. 8205

United States

H.R. 8205

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

Energy and Commerce Committee · Rep. Mike Quigley (D-IL)

The bill would extend funding through fiscal year 2031 for federal programs supporting research and development of treatments for ALS and other neurodegenerative diseases, including grants from the National Institutes of Health and Food and Drug Administration, as well as a partnership between the two agencies. It would also require the NIH to evaluate the safety and efficacy of experimental drugs and mandate that researchers report serious side effects, while directing the FDA to develop and publish a five-year plan to advance drug development and expand access to investigational treatments for these diseases.[AI-Generated]

Passed Senate (voice vote) 28 September 2026

Record as of 28 September 2026 — the most recent action in the official record. Status can lag; each step below carries its own date.

  1. 28 September 2026 Passed Senate (voice vote)

    What's next: Presidential review (±10 days)

  2. 23 July 2026 Placed on calendar (Senate)
  3. 22 July 2026 Passed House with amendment
    6 more actions
    1. 22 July 2026 Motion to reconsider laid on the table Agreed to without objection.
    2. 22 July 2026 Considered as unfinished business. (consideration: CR H5159)
    3. 20 July 2026 At the conclusion of debate, the chair put the question on the motion to suspend the rules. Mr. Guthrie objected to the vote on the grounds that a quorum was not present. Further proceedings on the motion were postponed. The point of no quorum was considered as withdrawn.
    4. 20 July 2026 DEBATE - The House proceeded with forty minutes of debate on H.R. 8205.
    5. 20 July 2026 Considered under suspension of the rules. (consideration: CR H4652-4654; text: CR H4653)
    6. 20 July 2026 Mr. Guthrie moved to suspend the rules and pass the bill, as amended.
  4. 9 July 2026 Placed on calendar (House)
  5. 9 July 2026 Reported by committee
    4 more actions
    1. 21 May 2026 Ordered to be Reported (Amended) by the Yeas and Nays: 46 - 0.
    2. 21 May 2026 Committee Consideration and Mark-up Session Held
    3. 13 May 2026 Forwarded by Subcommittee to Full Committee by Voice Vote.
    4. 13 May 2026 Subcommittee Consideration and Mark-up Session Held
  6. 6 April 2026 Referred to the Subcommittee on Health
  7. 6 April 2026 Referred to committee
  8. 6 April 2026 Introduced in House
This path starts where the bill does — its first action in the official record. Routine procedural steps sit in the “more actions” rows above rather than on the main line.

Read the live feed — on the site or in the app Look up H.R. 8205 on Congress.gov All US bills